rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Mary L. Smith

Director

Company insider

Files Form 4 as: Director, PTC Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
28
Buys
0
Sells
1
Bought
$0
Sold
$2.9M
Companies
1
Companies where not an officer
1
First trade
11 Jun 2021
Last trade
9 Jul 2026
Last filed
13 Jul 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
PTCT PTC TherapeuticsDirector · Biotechnology · last 9 Jul 20260 buys · 1 sell

Activity over time

1 Jul – 1 Oct
101 Jul1 Aug1 Sep1 Oct

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
9 Jul 2026filed 13 Jul 2026PTCT PTC TherapeuticsBiotechnologySEC FORM 4 Code M$430K10,000 at $42.95filing
9 Jul 2026filed 13 Jul 2026PTCT PTC TherapeuticsBiotechnologySEC FORM 4 Sold$900K10,000 at $90.00filing
9 Jul 2026filed 13 Jul 2026PTCT PTC TherapeuticsBiotechnologySEC FORM 4 Code M$251K5,834 at $42.95filing
9 Jul 2026filed 13 Jul 2026PTCT PTC Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—10,000 at $0.00filing
9 Jul 2026filed 13 Jul 2026PTCT PTC Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—5,834 at $0.00filing
9 Jul 2026filed 13 Jul 2026PTCT PTC TherapeuticsBiotechnologySEC FORM 4 Sold$525K5,834 at $90.00filing
9 Jul 2026filed 13 Jul 2026PTCT PTC Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—10,000 at $0.00filing
9 Jul 2026filed 13 Jul 2026PTCT PTC Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—5,834 at $0.00filing
9 Jul 2026filed 13 Jul 2026PTCT PTC TherapeuticsBiotechnologySEC FORM 4 Code M$430K10,000 at $42.95filing
9 Jul 2026filed 13 Jul 2026PTCT PTC TherapeuticsBiotechnologySEC FORM 4 Sold$900K10,000 at $90.00filing
9 Jul 2026filed 13 Jul 2026PTCT PTC TherapeuticsBiotechnologySEC FORM 4 Code M$251K5,834 at $42.95filing
9 Jul 2026filed 13 Jul 2026PTCT PTC TherapeuticsBiotechnologySEC FORM 4 Sold$525K5,834 at $90.00filing
2 Jan 2026filed 6 Jan 2026PTCT PTC TherapeuticsBiotechnologySEC FORM 4 Code A—4,000 at $0.00filing
2 Jan 2026filed 6 Jan 2026PTCT PTC Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—3,475 at $0.00filing
2 Jan 2026filed 6 Jan 2026PTCT PTC Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—3,475 at $0.00filing
2 Jan 2026filed 6 Jan 2026PTCT PTC TherapeuticsBiotechnologySEC FORM 4 Code A—4,000 at $0.00filing
3 Jan 2025filed 7 Jan 2025PTCT PTC Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—8,800 at $0.00filing
3 Jan 2025filed 7 Jan 2025PTCT PTC TherapeuticsBiotechnologySEC FORM 4 Code A—4,000 at $0.00filing
15 Feb 2024filed 16 Feb 2024PTCT PTC Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
15 Feb 2024filed 16 Feb 2024PTCT PTC TherapeuticsBiotechnologySEC FORM 4 Code A—4,000 at $0.00filing

Sectors

Health Care1

Buys in green, sells in red, by the company’s sector.

Related people

Michael SchmertzlerDirector · Director at Ptc Therapeutics, filing Form 4 there in the last year
Mark Elliott BouldingExec. VP and CLO · Exec. VP and CLO at Ptc Therapeutics, filing Form 4 there in the last year
Glenn Steele Jr.Director · Director at Ptc Therapeutics, filing Form 4 there in the last year
Matthew B. KleinChief Executive Officer · Chief Executive Officer at Ptc Therapeutics, filing Form 4 there in the last year
Hege Elisabeth Sollie-ZetlmayerDirector · Director at Ptc Therapeutics, filing Form 4 there in the last year
Donald J. TrumpPresident · Also traded PTCT in the last 90 days